Albright hereditary osteodystrophy (AHO) is caused by heterozygous deactivating GNAS1 mutations. There is a parent-of-origin effect. Maternally derived mutations are usually associated with resistance to parathyroid hormone termed "pseudohypoparathyroidism type Ia." Paternally derived mutations are associated with AHO but usually normal hormone responsiveness, known as "pseudo-pseudohypoparathyroidism." These observations can be explained by tissue-specific GNAS1 imprinting. Regulation of the genomic region that encompasses GNAS1 is complex. At least three upstream exons that splice to exon 2 of GNAS1 and that are imprinted have been reported. NESP55 is exclusively maternally expressed, whereas exon 1A and XLas are exclusively paternally expressed. We set out to identify the parental origin of GNAS1 mutations in patients with AHO by searching for their mutation in the overlapping transcripts. This information would be of value in patients with sporadic disease, for predicting their endocrine phenotype and planning follow-up. In doing so, we identified mutations that resulted in nonsense-mediated decay of the mutant Gsa transcript but that were detectable in NESP55 messenger RNA (mRNA), probably because they lie within its 3 untranslated region. Analysis of the NESP55 transcripts revealed the creation of a novel splice site in one patient and an unusual intronic mutation that caused retention of the intron in a further patient, neither of which could be detected by analysis of the Gsa complementary DNA. This cluster of overlapping transcripts represents a useful model system in which to analyze the effects that mutant sequence has on mRNA-in particular, splicing-and the mechanisms of nonsense-mediated mRNA decay.
Introduction

Albright hereditary osteodystrophy (AHO [MIM 103580])
is characterized by short adult stature, obesity, brachydactyly, and ectopic ossifications in ∼60% of patients (for review, see . It is frequently associated with mild-to-moderate mental handicap. A proportion of patients with AHO have associated end-organ resistance to parathyroid hormone (PTH), known as "pseudohypoparathyroidism type I" (PHP Ia). Those who have AHO and normal endocrine responsiveness are said to have "pseudo-pseudohypoparathyroidism" (PPHP).
Patients with PHP Ia usually manifest hypocalcemia together with hyperphosphatemia and raised PTH (in the presence of normal renal function and 25-hydroxycholecalciferol) at some point in childhood. In addition, they often have clinically significant thyroid-stimulating hormone (TSH) resistance resulting in hypothyroidism (Levine et al. 1983) . For reasons that are not clear, these patients frequently have intermittent prolonged periods of normocalcemia and normal thyroid function. As a result, it can be difficult to determine whether a normocalcemic, euthyroid patient with AHO has the PHP Ia form or the PPHP form, although PTH levels are usually elevated in patients with PHP Ia. In the past, the PHP Ia and PPHP forms could be distinguished by PTHstimulation testing, which was not possible here since the supply of synthetic PTH for human injection was discontinued.
Both the PHP Ia and PPHP forms of AHO are caused by heterozygous deactivating mutations within the GNAS1 gene, located on chromosome 20q13. GNAS1 consists of 13 coding exons, from which four common isoforms are generated through alternative splicing of exon 3 and use of alternative splice-acceptor sites one codon apart in exon 4 (Kozasa et al. 1988) . A variety of different frameshift, nonsense, and mis-
Figure 1
Schematic representation of the GNAS1 cluster, including exons 1-13 of GNAS1 and upstream imprinted exons NESP55, XLas, and exon 1A. a, Summary of imprinting. Arrows above and below depict paternally and maternally expressed transcripts, respectively. The transcripts for Gsa and XLas have ORFs starting in their unique 5 exons and ending in exon 13. Exons 2-13 of GNAS1 lie within the 3 UTR of NESP55. Exon 1A is probably not translated. b, Location of primers used to amplify the Gsa, NESP55, and exon 1A transcripts (not to scale).
sense mutations throughout the gene have been reported (for review, see Aldred and Trembath 2000) . GNAS1 is widely expressed and encodes the a subunit of the heterotrimeric G protein, Gs, which transduces signals between certain cell-surface receptors (including those for PTH, TSH, and thyrotropin-releasing hormone) and intracellular adenylyl cyclase (for review, see Bourne and Stryer 1992) . Patients with either form of AHO have an ∼50% reduction in bioactivity of the Gsa subunit in all tissues measured, including erythrocytes, lymphocytes, platelets, and fibroblasts (Farfel and Bourne 1980; Levine et al. 1980; Bourne et al. 1981; Farfel et al. 1982) . In families in which AHO is segregating, the strongest predictor of the endocrine phenotype is the parent of origin (Davies and Hughes 1993) . Maternal transmission is usually associated with the PHP Ia form, and paternal transmission is usually associated with the PPHP form, although there has been an exception (Schuster et al. 1994 ). These observations are best explained by a tissue-specific imprinting model in which GNAS1 is biallelically expressed in most tissues but maternally expressed in certain cells, such as those of the proximal renal tubule. The AHO phenotype results from a general 50% Gsa-bioactivity reduction caused by deactivating mutations of either allele, whereas associated PHP Ia occurs only if the maternal allele is mutated, since that is the only allele expressed in the imprinted tissues. Support for this model has come from Gnas knockout mice, from mice with uniparental disomy for the homologous region encompassing Gnas, and from studies of human pituitary and thyroid (Yu et al. 1998; Peters et al. 1999; Hayward et al. 2001; Germain-Lee et al. 2002; Mantovani et al. 2002) .
Regulation of the genomic region that encompasses GNAS1 is complex (see fig. 1a ). Three overlapping transcripts, each of which has an alternative upstream exon spliced to exons 2-13 of GNAS1, have been reported. Exon 1A lies ∼2.5 kb upstream of GNAS1 exon 1. Exon 1A-containing transcripts are exclusively paternally expressed in a wide range of tissues and are probably not translated. Exon 1A appears to be intimately involved in the tissue-specific imprinting of GNAS1, since individuals with abnormal imprinting of exon 1A-specifically, an unmethylated maternal allele-have isolated PTH resistance known as "PHP Ib" (Liu et al. 2000) . Another transcript, known as "extralarge Gsa" (XLas), comprises a novel exon, 35 kb upstream of GNAS1 exon 1, that forms a continuous ORF with exons 2-13 of GNAS1; this transcript is also exclusively paternally expressed. The third transcript, NESP55 (a neuroendocrine secretory protein), has a novel exon ∼14 kb upstream of XLas and is spliced to GNAS1 exons 2-13, which appear to lie within its 3 UTR. The function of NESP55 is not known, but it appears to be exclusively maternally expressed (Hayward et al. 1998) . NESP55 is spanned by a paternally expressed antisense transcript that originates upstream of XLas and that is likely to be involved in suppressing the paternal NESP55 allele (Hayward and Bonthron 2000) . Further complexity is suggested by the presence of an alternative 3 exon, contained within intron 3 of GNAS1, that includes an alternative stop codon and polyadenylation site (Crawford et al. 1993) .
We set out to test whether these overlapping imprinted transcripts could be used to determine the parental origin of GNAS1 mutations. That would be of potential clinical value for predicting the endocrine phenotype in patients with sporadic AHO and for quantifying the extent of the parental-origin effect, given that it may not be absolute. Using a common polymorphism (c.393T/C) in exon 5 of GNAS1, we have confirmed that imprinting of the NESP55 and exon 1A transcripts is conserved in control lymphoblastoid cell lines. We have tested a cohort of nine patients with AHO who have mutations in exons 2-13 of GNAS1 from whom lymphoblastoid cell lines were available. In one patient known to have inherited the condition from her mother and in a further five patients with de novo mutations who have PHP Ia, we have demonstrated that the mutation is present in the NESP55 transcript but not in the exon 1A-containing transcript, confirming that it originated on the maternal GNAS1 allele. In one patient with PPHP in whom paternal origin has been demonstrated previously and in two further patients with probable PPHP, paternal origin was confirmed.
Four of the patients in the cohort that we studied had mutations predicted to cause frameshifts and premature termination codons. These mutations were not detectable in the Gsa cDNA, presumably owing to nonsense-mediated decay (NMD) of mRNA. However, the mutations, which were all maternally derived, were detected in the NESP55 transcripts, where they lie within the 3 UTR. In one patient, a single-nucleotide substitution at position Ϫ11 from the intron 4 splice-acceptor site appears to have resulted in retention of intron 4 in the NESP55 transcript. In another patient, a single-nucleotide change at position Ϫ1 of the intron 7 splice-acceptor site resulted in the use of a novel splice-acceptor site 1 nt downstream in the NESP55 transcript.
Subjects and Methods
Patients
Patients with AHO were recruited through U.K. clinical geneticists. In some instances, affected parents were ascertained after the diagnosis of AHO in their child. Most patients were seen at home for examination and for collection of samples for baseline biochemistry, including urea, electrolytes, calcium, phosphate, albumin, creatinine, and thyroid function, as well as lymphocyte DNA and lymphoblastoid cell lines. Samples for PTH were not collected, because of the requirement for rapid separation of the plasma. When available, additional information was obtained from the local clinicians and hospital notes. For patients who were treated with vitamin D preparations and/or thyroxine, details of their biochemical results at presentation were obtained when possible from notes or the referring clinician. Ethical committee approval was obtained for the study.
DNA Preparation
DNA and RNA were extracted from Epstein-Barr virus-transformed lymphoblastoid cell lines, which were grown in RPMI media (Gibco BRL) with 10% fetal bovine serum (Sigma), 1% L-Glutamate (Gibco BRL), and 0.1% penicillin/streptomycin (Sigma). DNA was extracted using standard methods.
RNA Extraction and cDNA Synthesis
Total RNA was extracted from lymphoblast cell pellets and fetal tissue by using Trizol, following the manufacturer's instructions (Gibco BRL). Each sample was treated with DNase (Gibco BRL), and cDNA synthesis was performed on ∼2 mg of total RNA by using Superscript II (Gibco BRL), following the manufacturer's instructions. The reverse-transcriptase reaction contained both an oligo dT and a random nonomer primer. The resulting cDNA products were amplified using standard hypoxanthine-guanine phosphoribosyltransferase-gene primers and were visualized on a 2% agarose gel to detect genomic contamination.
Screening of GNAS1 Exons 2-13 and Adjacent Introns, by Use of Denaturing High-Performance Liquid Chromatography (DHPLC)
Previously reported mutations were confirmed in the cell lines by sequencing of the relevant exon, using BigDye terminator technology (Applied Biosystems), and were run on an ABI 377 DNA Sequencer. Screening for unknown mutations was performed using DHPLC (Transgenomic WAVE DNA Fragment Analysis System). The optimal column temperatures and acetonitrile gradients were calculated for each fragment by using the WAVEMaker program (conditions available on request). Each fragment was amplified using the primer sets and conditions listed in table 1, with Hot Star Taq polymerase (Qiagen), following the manufacturer's instructions. Any amplicons exhibiting altered elution peaks were sequenced as described above. 
Imprinting Analysis of NESP55, Exon 1A, and Gsa Transcripts in Lymphoblast and Fetal RNA
For the detection of heterozygotes for the exon 5 FokI polymorphism (c.393T/C), DNA extracted from normal lymphoblast cells and cDNA from fetal tissue samples was amplified using primers GNAS4F/GNAS5R, for the DNA samples, and GNAS4F1/GNAS6R1, for the cDNA samples, and Megamix PCR premix (Microzone) (table 1 and fig. 1b ). The products were digested with FokI (NEB) and were separated on a 2% agarose gel. Seven heterozygous normal control lymphoblast cDNA samples, two heterozygous fetal cDNAs (lung and kidney), and cDNA from patient AHO-33 were amplified for the NESP55, exon 1A, and Gsa transcripts, by using NESPF2/GNAS10R1, EX1ARNAF/GNAS10R1, and MET1F/GNAS10R1, respectively. The authenticity of each amplicon was verified by sequencing as described above (see the previous subsection). A second nested PCR was performed on 2 ml of the original product in a total reaction volume of 20 ml with GNAS4F1 (5 -labeled with FAM)/GNAS6R1, using Megamix PCR premix (Microzone). Ten microliters of the PCR product was digested with FokI (NEB) and separated on a 4% polyacrylamide gel on an ABI 377 DNA Sequencer.
Amplification and Sequencing of NESP55, Exon 1A, and Gsa Transcripts
NESP55, exon 1A, and Gsa transcripts were amplified from cDNA in all patients by using the primer combinations shown in table 2 and figure 1b. Primers and conditions are shown in table 1. In some patients, reamplification of the original NESP55 PCR by using a second nested primer set, NESPF2/GNAS11R2, was necessary. One and a half microliters of original NESP55 PCR product was reamplified in a total volume of 30 ml. All PCRs from cDNA were performed using Hot Star Taq polymerase (Qiagen), following the manufacturer's instructions. Exon 1A is GC rich, and all PCRs required the use of Q buffer (supplied with Hot Star Taq polymerase) and, also, the addition of 5% dimethyl sulfoxide in the sequencing reaction. All PCR products were sequenced using BigDye (Applied Biosystems) with a 96ЊC denaturing temperature and a 55ЊC annealing temperature, under conditions recommended in the kit. Sequencing in the forward direction was performed using NESPF2, EX1ARNAF, and nested primers GNAS4F1 (5 -TGA GAG GGC AAC CAA AGT G-3 ) and GNAS9F1 (5 -CAT GTT TGA CGT GGG TGG C-3 ), and the reverse strands were sequenced with the original PCR primer.
Results
GNAS1 Mutation Screening
Mutations were identified in nine patients from whom lymphoblastoid cell lines were available. Their clinical features are summarized in table 3, and mutations are summarized in table 4. All mutations are numbered according to the cDNA sequence reported by Kozasa et al. (1988) (see the Genome Database [GDB ID GDB:120628]).
AHO-17.-This patient with AHO and PHP has been reported previously . He has a de novo 43-bp deletion (c.278del43bp), extending from exon 4 across the splice-donor junction to intron 4, that is predicted to result in exon 4 skipping, causing a frameshift and premature termination six codons downstream in exon 5.
AHO-10.-This patient with AHO and PHP has been reported previously (Yu et al. 1995) . He has the common 4-bp deletion (c.565-568delGACT) in exon 7; this deletion is predicted to result in a frameshift and premature protein truncation. It has been shown by others that this mutation is not expressed in mRNA, presumably because of NMD (Weinstein et al. 1992) . The mutation was not present in his clinically normal mother. His father was deceased but had no known features of AHO.
AHO-15.-This patient with AHO and PHP has a GrA substitution (c.586-1GrA) at the splice-acceptor site of intron 7. Samples from her parents were not available. This mutation has not been reported previously. The mutation was predicted either to result in exon 8 skipping with a frameshift and premature termination in exon 9 or to form a weak novel splice-acceptor site 1 base downstream, resulting in a single-nucleotide deletion with a frameshift and premature termination in exon 8. This patient has AHO and evidence of resistance to TSH, suggesting that she may have the PHP form. Her mother and younger sister also have features of AHO. She was found to have a c.725CrT transition predicted to result in the nonconservative substitution of threonine by isoleucine at amino acid residue 242 in exon 10. This amino acid lies within one of the three switch regions of Gsa that are involved in conformational changes between the active and inactive states (Pennington 1994) . The mutation segregated with the AHO phenotype in the family and was not found in 300 unrelated chromosomes screened.
AHO-55.-This patient with AHO and PHP has a c.776ArT substitution predicted to result in the nonconservative substitution of glutamate by valine at amino acid 259 in exon 10. The mutation was not present in either of his clinically normal parents and was not found in 300 unrelated chromosomes screened. This residue is highly conserved across all Ga subunits and lies within the third switch region of Gsa (Pennington 1994) . The same amino acid substitution has been reported previously and has been shown to result in impaired adenylyl cyclase stimulation (Ahmed et al. 1998; Warner et al. 1999) .
AHO-33.-No mutations were identified in this patient with AHO and PHP, after screening GNAS1 exons 2-13 and adjacent splice sites by SSCP and DHPLC and sequencing of exon 1. She was heterozygous (ϩ/Ϫ) for the common FokI polymorphism in exon 5 in genomic DNA. However, analysis of Gsa cDNA from her lymphoblast cell line showed that she was only expressing her Ϫ allele. Her father was clinically normal and was shown to be homozygous for the FokI Ϫ allele. Her mother was deceased but was not known to have had AHO. It was assumed that this patient had an unidentified mutation on her maternally derived ϩ allele, resulting in NMD. Subsequent screening of the NESP55 transcript resulted in the identification of a single-nucleotide substitution (IVS4:Ϫ11ArG), within intron 4, that causes retention of intron 4 and predicted premature termination 21 codons into the intron-derived sequence ( fig. 2) .
AHO-11.-This patient with AHO and PPHP, con- ).
e Reported previously (Yu et al. 1995) .
f Reported previously . firmed by PTH-stimulation testing, has been reported previously ). She has a de novo single-nucleotide substitution (c.432ϩ1GrA), affecting the intron 5 splice-donor site, that is predicted to result in exon 5 skipping, confirmed by analysis of the Gsa and exon 1A cDNA transcripts ( fig. 3b ). Exon 5 skipping is not associated with any frameshift. AHO-278.-This patient has AHO with no history of any symptomatic endocrine abnormality and has normal baseline calcium and thyroid function. He was ascertained through his daughter, who has osteoma cutis. His mutation is identical to that in patient AHO-11, to whom he is unrelated.
AHO-13.-This patient with AHO has three children with AHO and PHP Ia, all of whom developed hypothyroidism and hypocalcemia requiring treatment within the first few years of life. She consented only for her samples to be included in the study. She was reported to have developed hypothyroidism at age 31 years, but there was no information available regarding her thyroid antibodies. She was normocalcemic and had never had symptomatic hypocalcemia. She was found to have a c.737TrC transition predicted to result in the nonconservative substitution of phenylalanine by serine at amino acid 246 in exon 10. In Ga subunits across all species, this residue is either phenylalanine or tyrosine (Pennington 1994) . The mutation was not found in 300 unrelated chromosomes screened.
Imprinting of NESP55 and Exon 1A Transcripts Is Conserved in Lymphoblastoid Cell Lines
Imprinting of NESP55 and XLas has been demonstrated in a range of human fetal tissues (Hayward et al. 1998; Hayward and Bonthron 2000) , and paternal expression of exon 1A has been demonstrated in cDNA extracted from whole blood (Liu et al. 2000) . However, skewed imprinting and loss of imprinting in lymphoblasts have occasionally been reported (Antequera et al. 1990; Kubota et al. 1996; Hannula et al. 2001) . For that reason, we tested whether imprinting of NESP55 and exon 1A was conserved in lymphoblastoid cell lines.
Genomic DNA from normal control lymphoblastoid cell lines and normal fetal tissue samples was typed for a common FokI restriction-enzyme polymorphism (c.393T/C; I131I) in exon 5 of GNAS1. Seven lymphoblastoid cell lines and two normal fetal tissue samples were found to be heterozygous (ϩ/Ϫ) (data not shown). cDNA from these samples was used to amplify the NESP55, exon 1A, and Gsa transcripts in separate reactions, using the appropriate 5 exon forward primer and a reverse primer in exon 10 of GNAS1 (giving three distinct products). The authenticity of the transcripts was confirmed by sequencing from exon 2 back to the 5 exon. The three amplicons were subsequently reamplified using nested exonic primers (a labeled forward primer in exon 4 and a reverse primer in exon 6), to generate smaller fluorescently labeled products encompassing the FokI polymorphism. The products were digested with FokI and were sized. FokI digestion of the initial PCR products was not attempted, because of the complexity introduced by alternative splicing of exon 3 and because of the presence of additional FokI sites. As expected, Gsa transcripts were biallelically expressed in both lymphoblasts and fetal tissue. As predicted, the NESP55 and exon 1A transcripts were found to be monoallelically expressed in all the normal lymphoblast and fetal samples. In addition, the NESP55 and exon 1A transcripts were confirmed to be oppositely imprinted ( fig. 4) .
Determining the Parental Origin of GNAS1 Mutations
The NESP55 and exon 1A transcripts were amplified from lymphoblastoid cDNA in separate reactions, using a forward primer in the unique 5 exon and a reverse primer in either exon 10 or exon 11 of GNAS1 (according to the mutation position). The NESP55 product was reamplified using nested primers, since the initial NESP55 PCR product was weak (possibly because of low copy
Figure 2
Sequence data from patient AHO-33. A heterozygous IVS4:Ϫ11ArG mutation was present in genomic DNA. Gsa cDNA amplification products showed only normal transcript, owing to NMD of the mutant transcript, whereas amplification of the NESP55 transcript revealed retention of intron 4. The base substitution is depicted in boldface. Intronic and exonic sequences are given in lowercase and uppercase, respectively. Exon 4 sequence is underlined. number in lymphoblasts). The NESP55 and exon 1A transcripts were then sequenced using internal primers spanning the mutation but avoiding the inclusion of exon 3 because of the complexity introduced by the alternative splicing. The results are summarized in table 4.
In two patients, the parental origin of the mutation was known. Patient AHO-29, with borderline low thyroxine, had a clinically affected mother in whom the mutation was also demonstrated. The mutation was confirmed to be present in the NESP55 transcript but not the exon 1A transcript. The converse was found in patient AHO-11, in whom the mutation was found in the exon 1A transcript while the NESP55 sequence was normal ( fig. 3b) . In this patient, a diagnosis of PPHP has been confirmed, in the past, by normal PTH-stimulation testing. In addition, her mutation has previously been shown to be paternally derived, using the nearby FokI polymorphism, for which she was informative ).
The results for the remaining patients are summarized in table 4. In each patient, the mutation was found in either the NESP55 transcript or the exon 1A transcript but not both. In the five patients with de novo mutations who have confirmed PHP Ia, the paternally derived exon 1A allele showed only normal sequence, whereas the maternally derived NESP55 allele carried only the mutated sequence.
In two normocalcemic adults with AHO, neither of whom had any history of hypocalcemia, the mutations were found to be of paternal origin, since they were present in the exon 1A transcript but not the NESP55 transcript.
Protein-Terminating Mutations That Were Undetectable in the Gsa Transcript Were Detected in NESP55 cDNA
In patient AHO-17, the mutation was predicted to result in skipping of exon 4 and a frameshift. Analysis
Figure 3
Sequence data showing genomic DNA and NESP55 and exon 1A cDNA products. a, Patient AHO-10. The heterozygous c.565-568delGACT deletion is present in genomic DNA, as denoted by the inverted triangle. Only deleted sequence is present in the NESP55 transcript, and only normal sequence is present in exon 1A, indicating that the GNAS1 mutation is maternally derived. b, Patient AHO-11. The heterozygous c.432ϩ1GrA intron 5 splice-site mutation is present in genomic DNA. In NESP55 cDNA, normal exon 5 splicing has occurred. In exon 1A cDNA, skipping of exon 5 has occurred, confirming that the GNAS1 mutation is paternally derived. Exonic sequence is given in uppercase, and intronic sequence is given in lowercase. Exons 4, 5, and 6 sequences are given in boldfaced, normal, and underlined text, respectively. of the Gsa mRNA showed only normal sequence, consistent with reduced expression or NMD affecting the mutant allele. Analysis of the NESP55 mRNA by using nested amplification from the unique 5 exon to exon 11 showed only an abnormally short product, the sequencing of which confirmed skipping of exon 4.
In patient AHO-10, who has the common c.565-568GACT deletion, we confirmed that the mutant Gsa mRNA was not detectable but that the 4-bp deletion was present in the NESP55 transcript ( fig. 3a) .
In patient AHO-15, with a mutation affecting the intron 7 splice-acceptor site, only normal Gsa transcript was present. Analysis of the NESP55 transcript revealed that the weak novel splice-acceptor site 1 nt downstream was used, resulting in a single-base deletion, which in the Gsa transcript would be predicted to cause a frameshift and premature termination eight codons downstream in exon 8 (fig. 5 ).
In patient AHO-33, no mutation had been found on screening of genomic DNA; however, she was heterozygous for the common FokI polymorphism, and only her paternally derived Gsa Ϫ allele could be amplified from lymphoblast cDNA. To confirm that the FokI ϩ allele was maternally derived, we amplified exons 4-6 of her NESP55 cDNA by using nested PCR. The resulting product was abnormally large, and sequencing revealed that intron 4 had been retained. The only demonstrable alteration in the exon 4/intron 4/exon 5 sequence was a single-nucleotide substitution (Ϫ11ArG) at position IVS4. In retrospect, the sequence change had resulted in an altered DHPLC elution peak of the amplicon encompassing exons 4 and 5. This had been discounted as being unlikely to be pathological after sequencing and analysis using a neural network splicepredictor program (see the Berkeley Drosophila Genome Project Web site), which did not predict any alteration
Figure 4
Imprinting of GNAS1 and overlapping transcripts in normal lymphoblast cell lines. The transcripts were amplified using an upstream primer in the unique exon and a downstream primer in exon 10 of GNAS1. Because of alternative splicing of exon 3 and multiple FokI restriction-enzyme cut sites, nested amplification from exons 4-6 was performed on each transcript prior to FokI digestion. The FokI Ϫ allele (c.393T) gave a 195-bp product, and the FokI ϩ allele (c.393C) gave two products, of 122 and 73 bp (only the 122-bp product was visualized). An electropherogram demonstrating the fragments from one cell line (sized on an ABI 377 sequencer) is shown. a, Monoallelic expression of exon 1A, with only the ϩ allele being present. b, Biallelic expression of Gsa, with Ϫ and ϩ alleles being present. c, Monoallelic expression of NESP55 (opposite to exon 1A), with only the Ϫ allele being present.
Figure 5
Effect of the c.586-1GrA mutation (patient AHO-15). The GrA substitution obliterates the normal AG acceptor site in intron 7 (underlined) and causes NMD of the mutant Gsa transcipt. Analysis of the NESP55 transcript reveals that exon skipping does not occur. Instead, the novel splice site created 1 nt downstream is used, resulting in deletion of a single G nucleotide with a frameshift and premature termination in exon 8. Consensus splice-acceptor sequence is defined as NCAGG (Shapiro and Senapathy 1987) . Intronic and exonic sequences are given in lowercase and uppercase, respectively. of the 3 splice site. No other sequence variant to explain the inclusion of intron 4 could be found, and the IVS4: Ϫ11ArG change has not been found in 70 control chromosomes. The inclusion of intron 4 in the Gsa transcript would be predicted to result in premature truncation 21 codons downstream.
Discussion
Determining the Parental Origin of GNAS1 Mutations
We have exploited two oppositely imprinted overlapping mRNA transcripts, to determine the parental origin of GNAS1 mutations in nine patients with AHO. This approach has previously been used to demonstrate the parental origin of activating GNAS1 mutations in pituitary adenomas (Hayward et al. 2001) . Using the maternally expressed NESP55 and paternally expressed exon 1A transcripts, we were able (1) to confirm the parent of origin in two patients for whom it was known (one maternal and one paternal) and (2) to demonstrate a maternal origin in five patients with PHP Ia. The present study included two adults with AHO whom we had classified as having likely PPHP, given that they were normocalcemic and had no history of hypocalcemia. One had developed hypothyroidism, at age 31 years, for which she was treated with thyroxine. Her three affected children all developed hypothyroidism between 1.5 and 4.75 years of age and hypocalcemia between 2.5 and 10.75 years of age. Her hypothyroidism could be a mild manifestation of PHP Ia or could be coincidental; in the absence of PTH-infusion testing, it is difficult to be sure. Nevertheless, it is of interest that both of these individ-
Figure 6
Splice-recognition sequences within GNAS1 intron 4. The putative branch site GCTAAAT (underlined) is disrupted by the IVS4:Ϫ11ArG mutation (arrow). A second possible upstream branch site, CCCTGAC, is also shown (dotted underline). The diamond symbol denotes the conserved adenine nucleotide within the branch sites. The unusually short polypyrimidine tract CATTTC is given in italics. Exon 5 sequence is given in uppercase. uals had mutations originating on their paternal allele and that neither had manifested any endocrine dysfunction in childhood or early adulthood, when the onset is typical. In fact, neither had come to medical attention prior to the diagnosis of AHO in their children. These results are in keeping with the observed parental-origin effects in familial AHO (Davies and Hughes 1993; .
This method allows for the determination of parental origin in any patient with a confirmed mutation in exons 2-13 of GNAS1. It is not applicable to patients with mutations in exon 1, since that exon is not present in any of the reported overlapping imprinted transcripts. It is of potential value in patients who are heterozygous for the common FokI polymorphism in exon 5 (i.e., in 50% of the cohort that we studied), who can quite simply be screened for the presence of NMD indicative of a truncating mutation within that transcript. Parental origin can be determined by typing of the NESP55 and exon 1A transcripts for the FokI polymorphism. We believe that, in the absence of PTH-stimulation testing, this technique could be useful for clinicians faced with a young patient with a de novo mutation and AHO who is normocalcemic and euthyroid at first presentation, since it would predict the likelihood of associated PHP Ia and would help guide the frequency of monitoring for hypocalcemia and hypothyroidism.
There have been relatively few reports of paternal transmissions of AHO, probably because normocalcemic, euthyroid patients are less likely to come to medical attention, biasing the ascertainment. In the few paternal transmissions that have been reported, there is one instance in which the offspring was found to have PTH resistance on stimulation testing (although all baseline hormone measurements were normal), indicating that the parental-origin effect may not be absolute (Schuster et al. 1994) . Use of the technique that we report allows the parental origin to be determined in most patients with sporadic disease. It could potentially increase the number of patients with AHO who have confirmed paternally derived GNAS1 mutations for endocrine evaluation. In turn, this could help quantify the predictive value of knowing the parental origin in determining the endocrine phenotype in AHO, given that the effect may not be absolute.
The Effects of Intronic Mutations on Splicing
Three of the mutations we report resulted in altered mRNA splicing detectable in the NESP55 transcript. Splice sites are characterized by a consensus nucleotide sequence at the 5 and 3 ends of the intron and a further consensus branch-site sequence upstream of the 3 acceptor site. These sites are recognized by small nuclear ribonuclear proteins that bind, forming a multisubunit RNA-protein complex known as the "spliceosome." This facilitates cleavage at the 5 end of the intron and formation of a lariat at the branch site, after which the 3 end of the intron is cleaved and the two exon ends are ligated (Ohshima and Gotoh 1987) . Branch sites have a consensus sequence of Y81 NY100 T87 R81 A100 Y94 (where "Y" denotes pyrimidine, "R" denotes purine, and "N" denotes any nucleotide) (Krainer and Maniatis 1988) , although definitive identification is often difficult. Within the branch site, the adenine residue is thought to be essential for lariat formation and successful splicing (Ohshima and Gotoh 1987) .
In patient AHO-17, deletion of the intron 4 splice-donor site was expected to result in exon 4 skipping. This was confirmed to have occurred in the NESP55 transcript.
In patient AHO-33, the intronic mutation (IVS4: Ϫ11ArG) 11 nt upstream of the intron 4 splice-acceptor site is of particular interest. We were unable to test whether it was de novo, because the mother of the patient was deceased. Prior to our analysis of the Gsa and NESP55 transcripts, testing with a splicepredictor program had indicated that it was not likely to be pathogenic. However, it resulted in retention of intron 4 in the NESP55 transcript, possibly as a result of altering the branch site. Nucleotides Ϫ10 to Ϫ16 upstream of the 3 acceptor site of intron 4 may represent a branch site, although the sequence does not conform exactly to the consensus ( fig. 2) . It is possible that the IVS4:Ϫ11ArG change disrupts the conserved adenine nucleotide, causing failure of the spliceosome to bind or incorrect formation of the lariat during splicing with resulting retention of intron 4 in the mature mRNA ( fig. 6 ).
In patient AHO-15, the 586-1GrA mutation affects the conserved guanine residue in the 3 acceptor site of intron 7. The effect of most splice-acceptor site mutations is skipping of the entire exon, which in the Gsa transcript would have resulted in exon 8 skipping with a frameshift and premature protein truncation in exon 9. Analysis with a neural network splice-predictor program (see the Berkeley Drosophila Genome Project Web site) showed that the normal 3 acceptor site of intron 7 had a score of 0.78 (where 1.0 is the most likely splice-acceptor site). While the 586-1GrA change could create an immediately adjacent novel 3 splice site, the predicted score for this site was 0.28 ( fig. 5) . Analysis of the NESP55 mRNA revealed that splicing does indeed occur at this adjacent site, resulting in deletion of a single G nucleotide (c.586delG), a frameshift, and predicted premature protein truncation in exon 8, rather than exon 9.
Although these splice events were the only ones we detected, we cannot exclude the possibility that other aberrantly spliced transcripts resulted that failed to amplify sufficiently for us to detect with the method used.
The Effects of Protein-Truncating Mutations on NMD
NMD is a mechanism that protects cells from mutations that yield truncated, potentially deleterious proteins. In mammalian cells, it appears to be largely dependent on pre-mRNA splicing during which a complex of proteins involved with the splicing or subsequent steps of mRNA transport becomes associated 20-24 nt upstream of the exon-exon junctions (where they are known as "destabilizing elements"). These proteins are stripped from the mRNA with the first passage of the ribosome during translation. If translation terminates prematurely, then proteins from the downstream destabilizing complex can interact with proteins in the normal translational termination complex and other proteins, to activate a decapping protein and subsequent rapid degradation of the mRNA by intracellular 5 r3 exonucleases (for review, see Maquat 2002) . The normal NESP55 transcript is unusual in having so many introns within its 3 UTR. It is believed that the destabilizing elements do not bind 3 to the constitutive termination codon. This is likely to explain the stability of the normal NESP55 transcript.
In patients in whom we found protein-truncating mutations, only normal Gsa transcript was found. The simplest explanation is that the mutations resulted in NMD of the mutant transcript, but we cannot exclude the possibility that low levels of mutant Gsa transcript were obscured by preferential amplification and detection of the normal allele. In each instance, we were able to consistently detect a mutant NESP55 transcript that, had the Gsa transcript been processed in the same way, would have been expected to result in protein truncation. It is likely that the mutant NESP55 transcript was not subject to NMD because the mutations lay within the 3 UTR. Nevertheless, it may be that our ability to detect the mutant NESP55 transcripts was more sensitive as a result of the monoallelic expression, rather than any increased stability compared to the mutant Gsa transcript. To detect the NESP55 transcript, even in the normal control lymphoblast cell lines, we found that it was necessary to perform a nested amplification, which is likely to reflect a low copy number in lymphocytes but may also have improved our detection of mutant NESP55 as compared to Gsa transcripts.
A Useful Model System for Analyzing the Effects on mRNA of Sequence Changes That Usually Result in NMD
It is well recognized that the classification of sequence changes as missense, frameshift, or splicing mutations can be inaccurate when based on inspection of the sequence alone. When possible, analysis of the mutant mRNA is desirable. Although the observation of NMD in many instances indicates the introduction of a premature termination codon, it obscures the precise effect that the mutant sequence has on the mRNA and its processing. In the patients with splicing and protein-truncating mutations whom we studied, the effects of the mutations were revealed through analysis of the NESP55 transcript. On the basis of our findings, we believe that the GNAS1 overlapping imprinted gene cluster represents an interesting model system for detailed study of the effects that altered intronic and exonic sequences have on mRNA splicing, since any mutation downstream of GNAS1 exon 1 is likely to be detectable in either the NESP55 or the exon 1A transcript, despite NMD of the Gsa transcript.
Genotype-Phenotype Correlations in AHO
GNAS1 mutations have the potential to affect the overlapping transcripts differently, depending on whether they occur in exon 1 or exons 2-13 and whether they occur on the maternal allele or the paternal allele. Mutations of exons 2-13 might be expected to have additional manifestations, given that they affect the overlapping transcripts as well. It seems unlikely that mutations of the maternal allele will exert any additional effects through alterations of NESP55. It is not yet clear whether paternally derived mutations in exons 2-13 will affect the function of the exon 1A transcript, but they would be expected to impair XLas. Careful molecular and clinical characterization of patients may reveal some genotypephenotype correlations in future, but, to date, there has been no obvious effect, other than that of parental origin on endocrine dysfunction. screening and the patients and their families who participated in this study.
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